Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019204 (hepatocellular carcinoma)
 71,386 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The antitumor effects against solid tumors, such as Meth A sarcoma, MH-134 hepatoma and colon 26 adenocarcinoma, were examined after intratumoral administration of liposomes and Tumor Necrosis Factor (TNF) solution. The antitumor effects of liposomes against solid tumors were superior to those of TNF solution. In particular, the antitumor effect of positively charged (decyl amine) liposomes was superior to that of negatively charged liposomes and TNF solution. Further, positively charged liposomes containing a higher dose of TNF than the solution could be administered without killing the mice, because of reduced side-effects. After intratumoral (Meth A sarcoma) administration, the TNF plasma concentration was determined in order to estimate the systemic side-effects of TNF. The area under curve (AUC) after administration of positively charged liposomes containing 6 times dose of TNF was about 1/30 the AUC after the administration of TNF solution. After administration of positively charged liposomes, TNF was mainly retained locally. Positively charged liposomes exhibited a stronger antitumor effect than the solution and had a lower AUC (about 1/180) than the solution. Consequently, some solid tumors could be completely cured by positively charged liposomes, because of their increased antitumor effect and reduced toxicity.
 ...
PMID:Positively charged liposomes containing tumor necrosis factor in solid tumors. 1072 86

Soluble Flk-1, a soluble vascular endothelial growth factor (VEGF) receptor, is a potent inhibitor of angiogenesis, which could restrain growth and metastasis of some experimental tumors. However, antiangiogenic agents alone cannot eradicate tumor completely, and should be combined with other therapy to enhance their effects. In this study, we evaluated the antitumor activity of the combination therapy in the immunocompetent BALB/c mice bearing H22 hepatoma and Meth A fibrosarcoma, respectively. Mice were treated with either msFlk-1 i.m. at 100 microg/mouse once every 3 days for four times from day 3 after the tumor cell injection, cisplatin cycled twice (2 mg/kg i.p. on days 4 and 11 after the tumor cell inoculation), or both agents together. Tumor growth and survival time were continually observed. Antiangiogenesis in vivo was determined by CD31 immunohistochemistry. Assessment of apoptotic cells and histological analysis was also conducted in tumor tissues. Our results showed that the combination therapy could evidently improve antitumor efficacy, including tumor growth suppression, mice survival prolongation, tumor cell apoptosis augmentation as well as neovascularization inhibition as compared with controls, without serious adverse effects. Our data suggest that the combination of DDP with msFlk-1 is more effective to suppress tumor growth in mice than either agent alone, and this combination regimen showed its potential for future clinical application.
 ...
PMID:Systemic inhibition of tumor growth by soluble Flk-1 gene therapy combined with cisplatin. 1679 69


<< Previous 1 2 3 4